Targeting Immunometabolism Mediated by CD73 Pathway inEGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance

被引:41
作者
Passarelli, Anna [1 ]
Aieta, Michele [1 ]
Sgambato, Alessandro [2 ]
Gridelli, Cesare [3 ]
机构
[1] Ctr Riferimento Oncol Basilicata IRCCS CROB, Dept Oncohematol, Med Oncol Unit, Rionero In Vulture, Italy
[2] Ctr Riferimento Oncol Basilicata IRCCS CROB, Lab Preclin & Translat Res, Rionero In Vulture, Italy
[3] SG Moscati Hosp, Div Med Oncol, Avellino, Italy
关键词
non-small cell lung cancer; epidermal growth factor receptor; immune metabolism; adenosine; CD73; immunotherapy; immune resistance; CHECKPOINT INHIBITORS; EMERGING CONCEPTS; ADVERSE EVENTS; ADENOSINE; GROWTH; IMMUNOTHERAPY; EXPRESSION; DOCETAXEL; BLOCKADE; THERAPY;
D O I
10.3389/fimmu.2020.01479
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite the relevant antitumor efficacy of immunotherapy in advanced non-small cell lung cancer (NSCLC), the results in patients whose cancer harbors activating epidermal growth factor receptor (EGFR) mutations are disappointing. The biological mechanisms underlying immune escape and both unresponsiveness and resistance to immunotherapy inEGFR-mutant NSCLC patients have been partially investigated. To this regard, lung cancer immune escape largely involves high amounts of adenosine within the tumor milieu with broad immunosuppressive effects. Indeed, besides immune checkpoint receptors and their ligands, other mechanisms inducing immunosuppression and including adenosine produced by ecto-nucleotidases CD39 and CD73 contribute to lung tumorigenesis and progression. Here, we review the clinical results of immune checkpoint inhibitors inEGFR-mutant NSCLC, focusing on the dynamic immune composition ofEGFR-mutant tumor microenvironment. The adenosine pathway-mediated dysregulation of energy metabolism in tumor microenvironment is suggested as a potential mechanism involved in the immune escape process. Finally, we report the strong rationale for planning strategies of combination therapy with immune checkpoints blockade and adenosine signaling inhibition to overcome immune escape and immunotherapy resistance inEGFR-mutated NSCLC.
引用
收藏
页数:11
相关论文
共 89 条
[41]   A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC [J].
Lisberg, A. ;
Cummings, A. ;
Goldman, J. W. ;
Bornazyan, K. ;
Reese, N. ;
Wang, T. ;
Coluzzi, P. ;
Ledezma, B. ;
Mendenhall, M. ;
Hunt, J. ;
Wolf, B. ;
Jones, B. ;
Madrigal, J. ;
Horton, J. ;
Spiegel, M. ;
Carroll, J. ;
Gukasyan, J. ;
Williams, T. ;
Sauer, L. ;
Wells, C. ;
Hardy, A. ;
Linares, P. ;
Lim, C. ;
Ma, L. ;
Adame, C. ;
Garon, Edward B. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1138-1145
[42]   Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer [J].
Lisberg, Aaron ;
Garon, Edward B. .
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (02) :195-197
[43]   Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis [J].
Mannavola, Francesco ;
Tucci, Marco ;
Felici, Claudia ;
Passarelli, Anna ;
D'Oronzo, Stella ;
Silvestris, Francesco .
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
[44]   The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma [J].
Marco, Tucci ;
Anna, Passarelli ;
Annalisa, Todisco ;
Francesco, Mannavola ;
Stefania, Stucci Luigia ;
Stella, D'Oronzo ;
Michele, Rossini ;
Marco, Taurisano ;
Loreto, Gesualdo ;
Franco, Silvestris .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
[45]   Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer [J].
Martinez, Pablo ;
Peters, Solange ;
Stammers, Timothy ;
Soria, Jean-Charles .
CLINICAL CANCER RESEARCH, 2019, 25 (09) :2691-2698
[46]   Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression [J].
Masuda, K. ;
Horinouchi, H. ;
Tanaka, M. ;
Higashiyama, R. ;
Shinno, Y. ;
Sato, J. ;
Yoshida, T. ;
Matsumoto, Y. ;
Goto, Y. ;
Kanda, S. ;
Yamamoto, N. ;
Ohe, Y. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S292-S293
[47]   Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth [J].
Mediavilla-Varela, Melanie ;
Luddy, Kimberly ;
Noyes, David ;
Khalil, Farah K. ;
Neuger, Anthony M. ;
Soliman, Hatem ;
Antonia, Scott J. .
CANCER BIOLOGY & THERAPY, 2013, 14 (09) :860-868
[48]   Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade [J].
Mittal, Deepak ;
Vijayan, Dipti ;
Smyth, Mark J. .
CANCER DISCOVERY, 2018, 8 (09) :1066-1068
[49]  
Monteiro Ines, 2018, Oncotarget, V9, P26659, DOI 10.18632/oncotarget.25426
[50]   Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Novello, S. ;
Barlesi, F. ;
Califano, R. ;
Cufer, T. ;
Ekman, S. ;
Levra, M. Giaj ;
Kerr, K. ;
Popat, S. ;
Reck, M. ;
Senan, S. ;
Simo, G. V. ;
Vansteenkiste, J. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2016, 27 :v1-v27